<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Medicare Part D Analysis | Aiden B. Jajo</title>
    <link rel="stylesheet" href="styles.css">
    <link rel="stylesheet" href="project-styles.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:wght@300;400;600&family=Work+Sans:wght@300;400;500&display=swap" rel="stylesheet">

</head>
<body>
    <!-- Navigation -->
    <nav class="nav">
        <div class="nav-container">
            <a href="index.html" class="nav-logo">Aiden B. Jajo</a>
            <div class="nav-links">
                <a href="index.html#about" class="nav-link">About</a>
                <a href="index.html#projects" class="nav-link">Projects</a>
                <a href="index.html#goals" class="nav-link">Goals</a>
                <a href="index.html#resume" class="nav-link">Resume</a>
                <a href="index.html#contact" class="nav-link nav-link-cta">Contact</a>
            </div>
        </div>
    </nav>

    <!-- Project Hero -->
    <section class="project-hero">
        <div class="container">
            <div class="breadcrumb">
                <a href="index.html">Home</a> / <a href="index.html#projects">Projects</a> / <span>Medicare Part D Analysis</span>
            </div>
            <h1 class="project-hero-title">The Billion-Dollar Opportunity in Medicare Part D</h1>
            <p class="project-hero-subtitle">Why are Medicare beneficiaries paying billions more than necessary when equally effective generic alternatives exist?</p>
            <div class="project-meta">
                <span class="meta-item"><strong>Tools:</strong> Python, Pandas, Tableau</span>
                <span class="meta-item"><strong>Dataset:</strong> 70,000+ drug-state records (2023)</span>
                <span class="meta-item"><strong>Focus:</strong> Cost Savings Analysis</span>
            </div>
        </div>
    </section>

    <!-- Executive Summary -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">Executive Summary</h2>
            <div class="content-block">
                <p>This analysis of 2023 Medicare Part D prescriber data across 359 medications and all 50 states identifies <strong>$2.68 billion in potential annual savings</strong> through a modest 25% improvement in generic drug adoption. The single largest opportunity ‚Äî <strong>$885 million</strong> ‚Äî is concentrated in just three insulin products where brand utilization exceeds 95% despite FDA-approved generic alternatives. Geographic analysis reveals an 11-percentage-point spread in generic adoption rates across states, with five states alone accounting for over $1.9 billion in recoverable savings. The root cause is not clinical necessity, but systemic friction in the prescribing and substitution process.</p>
            </div>
        </div>
    </section>

    <!-- Challenge Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">The Challenge</h2>
            <div class="content-block">
                <p class="lead-text">Working as a pharmacy clerk at an independent pharmacy in El Cajon, I see the same scenario play out every week: a Medicare patient hands me their prescription, I process it through their Part D plan, and their face falls when they see the copay.</p>
                
                <p>"Is there a cheaper version?" they ask. Sometimes there is, a generic that works exactly the same but costs a fraction of the price. Other times, their doctor specifically wrote for the brand name, and we're stuck.</p>
                
                <p>But here's what bothers me: even when generics are available, I see prescriptions come through for brand name medications that could easily be swapped. An insulin prescription that costs $800 when a $250 generic exists. An antipsychotic that runs $400 when the generic is $20. These aren't isolated cases, they're patterns.</p>
                
                <p>Insurance pricing often feels like a black box. This project analyzes Medicare Part D prescriber data from 2023 to quantify exactly how much money is being left on the table, and where the biggest opportunities for savings exist.</p>
            </div>
        </div>
    </section>

    <!-- Methodology Section -->
    <section class="project-section bg-light">
        <div class="container">
            <h2 class="section-title-small">Data & Methodology</h2>
            
            <div class="methodology-grid">
                <div class="method-card">
                    <div class="method-icon">üìä</div>
                    <h3>Data Source</h3>
                    <p>Medicare Part D Prescriber Data (2023) from CMS. The raw dataset contains over 3GB of prescriber-level records with key fields: <code>Gnrc_Name</code> (generic drug name), <code>Is_Brand</code> (brand vs. generic flag), <code>Prscrbr_State_Abrvtn</code> (state), <code>Tot_Drug_Cst</code> (total cost), <code>Tot_Clms</code> (total claims), and <code>Tot_Benes</code> (total beneficiaries). After filtering to medications that have both brand and generic versions in the dataset, 359 drugs remained for analysis across all 50 states.</p>
                </div>
                
                <div class="method-card">
                    <div class="method-icon">üßπ</div>
                    <h3>Data Processing</h3>
                    <p>The raw prescriber-level data was aggregated in two ways: (1) by drug and brand/generic status to produce national-level per-drug metrics, and (2) by state and brand/generic status to produce state-level adoption and cost profiles. Missing beneficiary counts were retained as-is rather than imputed, as claims and cost data were complete. Territory codes (e.g., PR, GU) were included in state-level views but flagged separately in geographic comparisons.</p>
                </div>
                
                <div class="method-card">
                    <div class="method-icon">‚öôÔ∏è</div>
                    <h3>Savings Calculation</h3>
                    <p>For each drug, potential savings were calculated as:<br><br>
                    <code>Savings (100%) = Brand Claims √ó (Avg Cost per Brand Claim ‚àí Avg Cost per Generic Claim)</code><br><br>
                    This represents the maximum recoverable cost if every brand claim were switched to its generic equivalent at current generic pricing. The <strong>25% adoption improvement scenario</strong> was chosen as the primary metric because it represents a realistic near-term policy target ‚Äî aggressive enough to be meaningful, but achievable without requiring universal substitution mandates. State-level savings were calculated by measuring each state's gap to the national average generic adoption rate (76.4%) and applying the cost differential to the estimated claim volume that would shift.</p>
                </div>
                
                <div class="method-card">
                    <div class="method-icon">‚ö†Ô∏è</div>
                    <h3>Insulin & Biosimilar Note</h3>
                    <p>A key assumption in this analysis is FDA-established clinical equivalency between brand and generic versions. This holds straightforwardly for small-molecule drugs. For insulin, however, the situation is more nuanced: many "generic" insulin products are technically <strong>biosimilars or follow-on biologics</strong>, not identical copies. The FDA has approved these as interchangeable for most patients, but some clinicians exercise caution with biosimilar substitution due to potential immunogenicity differences. The insulin savings figures should therefore be interpreted as an upper bound that assumes full clinical interchangeability, which current FDA guidance largely supports but does not universally mandate.</p>
                </div>

                <div class="method-card">
                    <div class="method-icon">üìà</div>
                    <h3>Analysis Tools</h3>
                    <p>Python (pandas, numpy, matplotlib, seaborn) for data ingestion, aggregation, feature engineering, and static visualizations. Tableau Public for the interactive dashboard enabling state-level and drug-level filtering. All source code and processed outputs are available on GitHub.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Key Findings Section -->
    <section class="project-section bg-light">
        <div class="container">
            <h2 class="section-title-small">Key Findings</h2>
            
            <!-- Finding 01 -->
            <div class="insight-block">
                <div class="insight-content">
                    <div class="insight-number">01</div>
                    <h3>Three Insulin Products Represent $885 Million in Potential Savings</h3>
                    <p>Insulin Aspart, Insulin Lispro, and Insulin Degludec showed 95 to 99% brand utilization despite available generics. These three medications alone represent the single largest savings opportunity in Medicare Part D.</p>
                    
                    <div class="key-stats">
                        <div class="stat-item">
                            <span class="stat-value">99%</span>
                            <span class="stat-label">brand usage for Insulin Aspart</span>
                        </div>
                        <div class="stat-item">
                            <span class="stat-value">$885M</span>
                            <span class="stat-label">potential savings from insulin alone</span>
                        </div>
                    </div>
                </div>
                <div class="insight-visual">
                    <img src="visual_1_top_savings.png" alt="Top 10 Medications by Savings Potential">
                    <p class="visual-caption">Top 10 medications ranked by potential annual savings with 25% generic adoption improvement</p>
                </div>
            </div>

            <div class="visual-pair">
                <div class="visual-item">
                    <img src="visual_2_cost_distribution.png" alt="Cost Distribution">
                    <p class="visual-caption">Distribution shows brand medications cost significantly more per claim than generics</p>
                </div>
                <div class="visual-item">
                    <img src="visual_3_brand_generic_composition.png" alt="Brand vs Generic Composition">
                    <p class="visual-caption">Stacked bars reveal insulin's 99% brand usage compared to better generic adoption in other drug classes</p>
                </div>
            </div>

            <!-- Finding 02 -->
            <div class="insight-block reverse">
                <div class="insight-visual">
                    <img src="visual_4_savings_matrix.png" alt="Savings Opportunity Matrix">
                    <p class="visual-caption">Each medication plotted by cost difference and savings potential. Insulin products cluster in the high impact quadrant.</p>
                </div>
                <div class="insight-content">
                    <div class="insight-number">02</div>
                    <h3>Brand Dominance in High Cost Medications is Extreme</h3>
                    <p>When visualizing the composition of prescriptions for top savings potential drugs, a clear pattern emerges. Insulin products show nearly complete brand dominance while other medication classes demonstrate that high generic adoption is achievable.</p>
                    
                    <p>This isn't about generic availability. The medications exist. This is about systemic barriers preventing their use.</p>
                </div>
            </div>

            <!-- Finding 03 -->
            <div class="insight-block">
                <div class="insight-content">
                    <div class="insight-number">03</div>
                    <h3>Your State Determines Your Generic Access</h3>
                    <p>Generic adoption rates range from 69.7% to over 81% depending on location. This 11 percentage point spread translates to hundreds of millions in unnecessary costs and suggests the problem isn't medical necessity but regional prescribing patterns.</p>
                </div>
                <div class="insight-visual">
                    <img src="visual_5_state_rankings.png" alt="State Rankings">
                    <p class="visual-caption">Top 15 and bottom 15 states by generic adoption rate. Geographic disparities are significant.</p>
                </div>
            </div>

            <!-- Finding 04 -->
            <div class="insight-block reverse">
                <div class="insight-visual">
                    <img src="visual_6_state_opportunity.png" alt="State Opportunity Analysis">
                    <p class="visual-caption">States plotted by generic adoption and savings potential. Large bubbles below the national average represent the biggest opportunities.</p>
                </div>
                <div class="insight-content">
                    <div class="insight-number">04</div>
                    <h3>Five States Represent Over $1.9 Billion in Savings Opportunity</h3>
                    <p>New York alone could save nearly $978 million annually just by reaching the national average generic adoption rate of 76.4%. Indiana ($258M), Michigan ($256M), California ($222M), and Alabama ($214M) round out the top five ‚Äî together representing over $1.9 billion in concentrated, geographically targetable savings opportunity.</p>
                </div>
            </div>

            <!-- Finding 05 -->
            <div class="insight-block highlight">
                <div class="insight-icon">üí°</div>
                <div class="insight-content">
                    <h3>Systemic Friction, Not Clinical Necessity, Drives Brand Use</h3>
                    <p>From behind the pharmacy counter, I see the real barriers. When a prescription comes through for a brand name medication and I see a generic alternative, I can't just switch it. I need prescriber authorization. So I call the doctor's office.</p>
                    
                    <p>Sometimes the medical assistant says "generic is fine" and we make the switch. Sometimes the doctor wants brand specifically. But often the response is "that's just what the doctor always writes." Or they don't return my call. The patient needs their medication now, so we fill the brand because that's what's on the prescription.</p>
                    
                    <p>Multiply this by millions of prescriptions nationwide and you see how systemic friction, not clinical necessity, drives brand utilization.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Impact & Path Forward Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">The Path Forward</h2>
            
            <div class="takeaway-grid">
                <div class="takeaway-card">
                    <h3>Target High Impact Medications</h3>
                    <p>Focus immediate intervention on insulin and the top 10 medications by savings potential.</p>
                    <ul>
                        <li>Provider education campaigns highlighting generic efficacy</li>
                        <li>Automatic substitution policies with clinical override</li>
                        <li>Patient education at point of prescription</li>
                    </ul>
                </div>
                
                <div class="takeaway-card">
                    <h3>Geographic Targeting</h3>
                    <p>Pilot intensive interventions in underperforming states with large Medicare populations.</p>
                    <ul>
                        <li>New York: $978M potential savings</li>
                        <li>Indiana: $258M potential savings</li>
                        <li>Michigan: $256M potential savings</li>
                        <li>California: $222M potential savings</li>
                        <li>Alabama: $214M potential savings</li>
                    </ul>
                </div>
                
                <div class="takeaway-card">
                    <h3>Prescriber Feedback Systems</h3>
                    <p>Provide physicians with data driven insights on their prescribing patterns.</p>
                    <ul>
                        <li>Generic prescription rate versus peers</li>
                        <li>Estimated patient cost savings</li>
                        <li>Clinical outcomes demonstrating equivalency</li>
                    </ul>
                </div>
                
                <div class="takeaway-card" style="padding: 0; border: none; background: transparent;">
                    <img src="visual_7_waterfall.png" alt="Savings Waterfall" style="width: 100%; height: auto; border-radius: 4px;">
                    <p class="visual-caption" style="margin-top: 1rem;">Projected impact of 25% generic adoption improvement</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Dashboard Section -->
    <section class="project-section bg-dark">
        <div class="container">
            <h2 class="section-title-small light">Interactive Dashboard</h2>
            <p class="dashboard-intro">Explore the data yourself using this interactive Tableau dashboard. Filter by state, medication, and cost metrics to understand how different factors affect savings potential.</p>
            
            <div class="tableau-container">
                <div class='tableauPlaceholder' id='viz1769411780219' style='position: relative'>
                    <noscript>
                        <a href='#'>
                            <img alt='Dashboard 1 ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Ta&#47;Tableau_17693874392490&#47;Dashboard1&#47;1_rss.png' style='border: none' />
                        </a>
                    </noscript>
                    <object class='tableauViz' style='display:none;'>
                        <param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' />
                        <param name='embed_code_version' value='3' />
                        <param name='site_root' value='' />
                        <param name='name' value='Tableau_17693874392490&#47;Dashboard1' />
                        <param name='tabs' value='no' />
                        <param name='toolbar' value='yes' />
                        <param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Ta&#47;Tableau_17693874392490&#47;Dashboard1&#47;1.png' />
                        <param name='animate_transition' value='yes' />
                        <param name='display_static_image' value='yes' />
                        <param name='display_spinner' value='yes' />
                        <param name='display_overlay' value='yes' />
                        <param name='display_count' value='yes' />
                        <param name='language' value='en-US' />
                    </object>
                </div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1769411780219');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    if ( divElement.offsetWidth > 800 ) { 
                        vizElement.style.width='100%';
                        vizElement.style.height='900px';
                    } else if ( divElement.offsetWidth > 500 ) { 
                        vizElement.style.width='100%';
                        vizElement.style.height='850px';
                    } else { 
                        vizElement.style.width='100%';
                        vizElement.style.height='1000px';
                    }
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
            
            <div class="dashboard-links">
                <a href="https://public.tableau.com/app/profile/aiden.jajo/viz/Tableau_17693874392490/Dashboard1" class="btn btn-secondary" target="_blank">Open in Tableau Public ‚Üí</a>
            </div>
        </div>
    </section>

    <!-- Impact & Takeaways Section -->
    <section class="project-section bg-light">
        <div class="container">
            <h2 class="section-title-small">Impact & Takeaways</h2>
            
            <div class="takeaway-grid">
                <div class="takeaway-card">
                    <h3>For Policymakers</h3>
                    <ul>
                        <li>$885M from insulin alone justifies immediate policy intervention</li>
                        <li>Geographic targeting offers concentrated ROI in underperforming states</li>
                        <li>Systemic barriers are fixable with targeted prescriber and patient education</li>
                    </ul>
                </div>
                
                <div class="takeaway-card">
                    <h3>For Healthcare Systems</h3>
                    <ul>
                        <li>Generic substitution protocols could save billions system wide</li>
                        <li>Pharmacy level interventions show high potential for impact</li>
                        <li>Provider feedback systems work for changing prescribing behavior</li>
                    </ul>
                </div>
                
                <div class="takeaway-card">
                    <h3>For Patients</h3>
                    <ul>
                        <li>Ask your doctor about generic alternatives for every prescription</li>
                        <li>Geographic location affects your likelihood of receiving generics</li>
                        <li>Cost barriers to essential medications like insulin are solvable</li>
                    </ul>
                </div>
            </div>
            
            <div class="limitations">
                <h3>Limitations & Future Work</h3>
                <p><strong>Clinical equivalency assumption.</strong> This analysis assumes that every brand prescription could be switched to its generic equivalent without affecting patient outcomes. For small-molecule drugs, this is well-supported by FDA bioequivalence standards. For insulin and other biologics, the picture is more nuanced ‚Äî biosimilars are not chemically identical to reference products, and a small subset of patients may experience sensitivity differences. The insulin savings figures ($885M) should be understood as an upper bound under full interchangeability.</p>
                <p><strong>What the data cannot tell us.</strong> The CMS dataset captures cost, claims volume, and geography ‚Äî but not the reasons behind prescribing decisions. We cannot distinguish between brand prescriptions driven by clinical preference, prior authorization outcomes, patient requests, or simply default prescribing habits. Prescriber-level data would be needed to separate these factors. Additionally, the dataset does not include patient outcome information, so we cannot directly validate that generic substitution maintained quality of care in practice.</p>
                <p><strong>Savings model assumptions.</strong> The 25% adoption improvement scenario assumes generic pricing remains stable as substitution volume increases. In practice, large-scale shifts in demand could affect generic pricing ‚Äî potentially reducing per-claim savings. The model also assumes no additional friction costs (e.g., prior authorization delays, therapeutic monitoring) associated with switching. These factors would likely reduce, but not eliminate, the identified savings opportunity.</p>
                <p><strong>Future directions.</strong> The most impactful extensions of this work would be: (1) longitudinal analysis tracking generic adoption trends year-over-year to identify whether natural market forces are already narrowing the gap; (2) prescriber-level disaggregation to identify specific high-brand-preference providers for targeted outreach; (3) integration of FDA biosimilar approval timelines to model how new generic entries may shift the opportunity landscape; and (4) incorporation of socioeconomic and demographic factors that may correlate with both prescribing patterns and patient health outcomes.</p>
            </div>
        </div>
    </section>

    <!-- Technical Implementation Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">Technical Implementation</h2>
            
            <div class="tech-code-section">
                <h3>Core Savings Calculation</h3>
                <p>The heart of the analysis: aggregating raw prescriber data by drug and brand/generic status, then computing per-claim cost differentials and projecting savings scenarios.</p>
                <div class="code-block">
                    <pre><code># Aggregate prescriber-level data by drug and brand/generic status
drug_summary = df.groupby(['Gnrc_Name', 'Is_Brand']).agg(
    Total_Cost=('Tot_Drug_Cst', 'sum'),
    Total_Claims=('Tot_Clms', 'sum'),
    Total_Benes=('Tot_Benes', 'sum')
).reset_index()

# Pivot to get brand and generic metrics side by side
brand = drug_summary[drug_summary['Is_Brand'] == True].set_index('Gnrc_Name')
generic = drug_summary[drug_summary['Is_Brand'] == False].set_index('Gnrc_Name')

# Only analyze drugs that have BOTH brand and generic versions
common_drugs = brand.index.intersection(generic.index)

# Calculate average cost per claim and the savings differential
savings_df['Avg_Cost_Brand'] = brand.loc[common_drugs, 'Total_Cost'] / brand.loc[common_drugs, 'Total_Claims']
savings_df['Avg_Cost_Generic'] = generic.loc[common_drugs, 'Total_Cost'] / generic.loc[common_drugs, 'Total_Claims']
savings_df['Cost_Difference'] = savings_df['Avg_Cost_Brand'] - savings_df['Avg_Cost_Generic']

# Project savings: what if every brand claim switched to generic pricing?
savings_df['Potential_Savings_100pct'] = brand.loc[common_drugs, 'Total_Claims'].values * savings_df['Cost_Difference']
# Conservative 25% adoption improvement scenario
savings_df['Potential_Savings_25pct'] = savings_df['Potential_Savings_100pct'] * 0.25</code></pre>
                </div>
            </div>

            <div class="tech-details">
                <div class="tech-item">
                    <h3>Data Pipeline</h3>
                    <p>3GB of raw CMS prescriber records were ingested with pandas, filtered to the 359 drugs with both brand and generic versions, then aggregated at both the national (per-drug) and state levels. Feature engineering produced brand utilization rates, cost differentials, and savings projections under multiple adoption scenarios.</p>
                    <div class="tech-tags">
                        <span class="tech-tag">pandas</span>
                        <span class="tech-tag">numpy</span>
                        <span class="tech-tag">3GB raw data</span>
                    </div>
                </div>
                
                <div class="tech-item">
                    <h3>Visualization</h3>
                    <p>Static charts (top-10 rankings, cost distributions, state comparisons, opportunity scatter plot, waterfall) were generated with matplotlib and seaborn for publication quality. An interactive Tableau dashboard enables filtering by state, medication, and cost metrics.</p>
                    <div class="tech-tags">
                        <span class="tech-tag">matplotlib</span>
                        <span class="tech-tag">seaborn</span>
                        <span class="tech-tag">Tableau Public</span>
                    </div>
                </div>
            </div>
            
            <div class="project-links">
                <a href="https://github.com/aidenjajo" class="btn btn-primary" target="_blank">View on GitHub ‚Üí</a>
                <a href="https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers" class="btn btn-secondary" target="_blank">Download CMS Data</a>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2026 Aiden B. Jajo. Built with purpose.</p>
        </div>
    </footer>
</body>
</html>
